Elna van der Ryst

4.0k total citations · 1 hit paper
58 papers, 2.6k citations indexed

About

Elna van der Ryst is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Elna van der Ryst has authored 58 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Virology, 34 papers in Infectious Diseases and 21 papers in Epidemiology. Recurrent topics in Elna van der Ryst's work include HIV Research and Treatment (39 papers), HIV/AIDS drug development and treatment (25 papers) and HIV/AIDS Research and Interventions (16 papers). Elna van der Ryst is often cited by papers focused on HIV Research and Treatment (39 papers), HIV/AIDS drug development and treatment (25 papers) and HIV/AIDS Research and Interventions (16 papers). Elna van der Ryst collaborates with scholars based in United Kingdom, United States and South Africa. Elna van der Ryst's co-authors include Mike Westby, Caroline E. Ridgway, Ian James, T.M. Jenkins, Anton Pozniak, Mike Youle, Nathan Clumeck, Howard Mayer, James Goodrich and John F. Sullivan and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and PLoS ONE.

In The Last Decade

Elna van der Ryst

55 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Elna van der Ryst

Since Specialization

Citations

This map shows the geographic impact of Elna van der Ryst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elna van der Ryst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elna van der Ryst more than expected).

Fields of papers citing papers by Elna van der Ryst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elna van der Ryst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elna van der Ryst. The network helps show where Elna van der Ryst may publish in the future.

Co-authorship network of co-authors of Elna van der Ryst

This figure shows the co-authorship network connecting the top 25 collaborators of Elna van der Ryst. A scholar is included among the top collaborators of Elna van der Ryst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elna van der Ryst. Elna van der Ryst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Maraviroc â€“ A CCR5 Antagonist for the Treatment of HIV-1 Infection 2015 ·Frontiers in Immunology ·Elna van der Ryst	43
2	Vaccination of Chimpanzees against HIV-1 2015 ·Antibiotics and chemotherapy/Antibiotica et chemotherapia ·(unknown), Elna van der Ryst, Patricia N. Fultz, Marc Girard	0
3	An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index 2014 ·BMC Public Health ·(unknown), Pieter Krüger, (unknown), (unknown), Elna van der Ryst	92
4	The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691) 2011 ·Clinical Pharmacology & Therapeutics ·Mark Fidock, (unknown), Carl Laxton, (unknown), (unknown), (unknown), Peter Colman, Vinay Kumar, (unknown), Katherine Wright, Subasree Srinivasan, Khurram Rana, Charles Craig, Nigel Horscroft, Manos Perros, Michael Westby, Robert O. Webster, Elna van der Ryst	64
5	Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials 2010 ·HIV Clinical Trials ·Mark Nelson, Martin Fisher, Juan González‐García, Jürgen K. Rockstroh, David Weinstein, Hernán Valdez, Howard Mayer, Elna van der Ryst, J. M. Goodrich, N. Pham Dang	1
6	35 GENOTYPIC CHARACTERISATION OF FILIBUVIR (PF-00868554) RESISTANCE IN PATIENTS RECEIVING FOUR WEEKS CO-ADMINISTRATION OF FILIBUVIR WITH PEGIFN/RBV (12 WEEK ANALYSIS) 2010 ·Journal of Hepatology ·Jo Mori, Jennifer Hammond, S. Srinivasan, (unknown), Elna van der Ryst	7
7	Hepatic safety and tolerability in the maraviroc clinical development program 2010 ·AIDS ·Ayman Ayoub, (unknown), James Goodrich, Jayvant Heera, Andy I. M. Hoepelman, Jacob Lalezari, (unknown), Mark Nelson, Elna van der Ryst, Howard Mayer	12
8	A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1 2009 ·The Journal of Infectious Diseases ·Michael S. Saag, James Goodrich, Gerd Fätkenheuer, Bonaventura Clotet, Nathan Clumeck, John F. Sullivan, Mike Westby, Elna van der Ryst, Howard Mayer, (unknown)	108
9	Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications 2009 ·Methods in enzymology on CD-ROM/Methods in enzymology ·(unknown), Sarah Able, Paul Griffin, (unknown), Ian James, Malcolm Macartney, (unknown), James E. Mills, Carolyn Napier, Iva Navrátilová, Manos Perros, (unknown), (unknown), Elna van der Ryst, Mike Westby, Patrick Dorr	13
10	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection breakdown → 2008 ·New England Journal of Medicine ·Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey P. Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, (unknown), (unknown), John F. Sullivan, Caroline E. Ridgway, Steve Felstead, Michael W. Dunne, Elna van der Ryst, Howard Mayer	570
11	Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 2005 ·Nature Medicine ·Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson, Andreas Plettenberg, Schlomo Staszewski, Andy I. M. Hoepelman, Michael S. Saag, Frank D. Goebel, Jürgen K. Rockstroh, Bruce J. Dezube, T.M. Jenkins, (unknown), John Sullivan, Caroline E. Ridgway, Sylvie Abel, Ian James, Mike Youle, Elna van der Ryst	386
12	Progress in HIV vaccine research 2002 ·Oral Diseases ·Elna van der Ryst	1
13	HIV/AIDS-related knowledge, attitudes and practices among South African military recruits. 2001 ·PubMed ·Elna van der Ryst, G Joubert, (unknown), Christo Heunis, (unknown), Carolyn Williamson	12
14	Lessons learned in establishing a randomised controlled trial to investigate the effect of vitamin A on vertical transmission of HIV-1. 2000 ·(unknown), Wilhelm J. Steinberg, G Joubert, (unknown), (unknown), (unknown), Elna van der Ryst	4
15	Allelic frequencies of host genetic variants influencing susceptibility to HIV-1 infection and disease in South African populations 2000 ·AIDS ·Carolyn Williamson, Shayne Loubser, (unknown), G Joubert, Teresa Smit, (unknown), (unknown), Mark E. Cooper, Elna van der Ryst	35
16	Psychiatric co-morbidity in South African HIV/AIDS patients 1999 ·South African Medical Journal ·(unknown), (unknown), (unknown), (unknown), G Joubert, Elna van der Ryst	24
17	Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes 1998 ·Research in Virology ·Elna van der Ryst, Tadashi Nakasone, André Habel, A Venet, E Gomard, Ralf Altmeyer, Marc Girard, Andrew M. Borman	13
18	Correlation Among Total Lymphocyte Count, Absolute CD4+ Count, and CD4+ Percentage in a Group of HIV-1-Infected South African Patients 1998 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Elna van der Ryst, (unknown), G Joubert, (unknown), (unknown), (unknown), (unknown), (unknown)	41
19	Genital Infection of Female Chimpanzees with Human Immunodeficiency Virus Type 1 1998 ·AIDS Research and Human Retroviruses ·Marc Girard, James Mahoney, Qing Wei, Elna van der Ryst, Elizabeth Muchmore, Françoise Barré‐Sinoussi, Patricia N. Fultz	35
20	Challenge of Chimpanzees Immunized with a Recombinant Canarypox-HIV-1 Virus 1997 ·Virology ·Marc Girard, Elna van der Ryst, Françoise Barré‐Sinoussi, Peter L. Nara, James Tartaglia, Enzo Paoletti, Christine Blondeau, Myra Jennings, Florence Verrier, Bernard Meignier, Patricia N. Fultz	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact